Cargando…

Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia

Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Alexander T, Gukasyan, Janet, Arabian, Sarkis, Wang, Sharon, Neeki, Michael M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235874/
https://www.ncbi.nlm.nih.gov/pubmed/34194882
http://dx.doi.org/10.7759/cureus.15280
_version_ 1783714419117654016
author Phan, Alexander T
Gukasyan, Janet
Arabian, Sarkis
Wang, Sharon
Neeki, Michael M
author_facet Phan, Alexander T
Gukasyan, Janet
Arabian, Sarkis
Wang, Sharon
Neeki, Michael M
author_sort Phan, Alexander T
collection PubMed
description Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications.
format Online
Article
Text
id pubmed-8235874
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82358742021-06-29 Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia Phan, Alexander T Gukasyan, Janet Arabian, Sarkis Wang, Sharon Neeki, Michael M Cureus Internal Medicine Infection by severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) is known to have the highest mortality rate among the elderly and those with pre-existing medical conditions. Viral load has been directly correlated with increased risk of mortality in hospitalized patients. Once infected, symptoms first arise approximately six to seven days later followed by immunoglobulin M (IgM) antibodies appearing 8-12 days after onset of clinical symptoms. Recent studies have noted that the monoclonal antibody combination of casirivimab and imdevimab (REGN-COV2) effectively reduces viral load in infected seronegative non-hospitalized patients. However, research supporting the use of REGN-COV2 in an inpatient setting is limited. We present the case of a 45-year-old male with confirmed SARS-CoV-2 infection with moderate dyspnea and progressive worsening of his symptoms over a week period. The patient showed drastic improvement of his symptoms after a single low-dose regimen of REGN-COV2 infusion while admitted to the hospital and was subsequently discharged without further medical complications. Cureus 2021-05-27 /pmc/articles/PMC8235874/ /pubmed/34194882 http://dx.doi.org/10.7759/cureus.15280 Text en Copyright © 2021, Phan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Phan, Alexander T
Gukasyan, Janet
Arabian, Sarkis
Wang, Sharon
Neeki, Michael M
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title_full Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title_fullStr Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title_full_unstemmed Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title_short Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 Pneumonia
title_sort emergent inpatient administration of casirivimab and imdevimab antibody cocktail for the treatment of covid-19 pneumonia
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235874/
https://www.ncbi.nlm.nih.gov/pubmed/34194882
http://dx.doi.org/10.7759/cureus.15280
work_keys_str_mv AT phanalexandert emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia
AT gukasyanjanet emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia
AT arabiansarkis emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia
AT wangsharon emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia
AT neekimichaelm emergentinpatientadministrationofcasirivimabandimdevimabantibodycocktailforthetreatmentofcovid19pneumonia